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Objectives: A pilot study showed that an internet-based self-management program improves 
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internet-based self-management program to an educational book developed for people with 
SSc in measures of self-efficacy and other patient-reported outcomes. 
Methods: A 16-week randomized, controlled trial. 
Results: Of the 267 participants who completed baseline questionnaires and were randomized 
to the intervention (internet) or control (book) condition, 123 (93%) in the internet and 124 
(94%) in the control completed the 16-week RCT. The mean (SD) age of all participants was 53.7 
(11.7) years, 91% were female, and 79.4% had some college or a higher degree. The mean (SD) 
disease duration after diagnosis of SSc was 8.97 (8.50) years. There were no statistical 
differences between the 2 groups for the primary outcome measure (PROMIS Self Efficacy 
Managing Symptoms: mean change of 0.35 in the internet group vs. 0.94 in control group, 
p=0.47) and secondary outcome measures, except the EQ5D visual analog scale (p=0.05). 
Internet group participants agreed that the self-management modules were of importance to 
them, the information was presented clearly, and the website was easy to use and at an 
appropriate reading level. 
Conclusion: Our RCT showed that the internet-based self-management website was not 
statistically superior to an educational patient-focused book in improving self-efficacy and other 




Significance of Innovation 
1.       Systemic sclerosis (SSc) is a rare disease with many patients who do not have access to 
education programs. 
2.       We performed a randomized controlled trial comparing an internet-based self-
management program to an educational book in measures of self-efficacy and other 
patient-reported outcomes. 
3.       Self-management website was not superior to an educational patient-focused book in 
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4.       The participants were enthusiastic for the content and presentation of the self-




Systemic sclerosis (SSc) is a rare autoimmune disease that universally affects the skin 
and is associated with aberrant vasculopathy and fibrosis of internal organs(1, 2). Currently, 
there is no cure for SSc. In addition to having the highest mortality rate among the rheumatic 
diseases, 
Because SSc is a rare disease, many people with SSc do not have support or access to 
education programs or support groups. To address the lack of educational programs, a self-
management program consisting of a workbook and DVD was developed and then tested in a 
small sample of participants with SSc(4). Improvements in pain, depression, and fatigue, as well 
as positive feedback from the participants, led to the conversion of all the modules in the 
booklet and the DVD to an internet format. In a pilot study of the internet version of the self –
management program, participants logged on to a website and proceeded through the 
modules and learning activities at their own pace over 10 weeks(5). Participants were 
encouraged to log on to the Discussion Board, an interactive component of the website, and 
respond to discussion questions posted for each module.  The pilot study showed statistically 
significant and positive changes for self-efficacy, ability to manage care, health efficacy, fatigue, 
and depression(5).  
SSc manifests with disfigurement, hand contractures, fatigue, poor sleep disorders, 
low self-esteem, pain, and severe Raynaud’s phenomenon—all associated with significant 
functional and work disability, and a decrement in quality of life. In addition, loss of productivity 
in the United States is estimated to be $10,764 per year(3).  
Since the initial development of the self-management program, new therapies and 
recommendations for laboratory and diagnostic tests and pharmacological treatments have 
emerged(1). Thus, the self-management program was revised and updated with input from 
patient partners and stakeholders (Scleroderma Foundation and Scleroderma Research 
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evaluate the efficacy of the internet-based self-management program vs. the patient book 
developed for people with SSc in improving self-efficacy and other patient-reported outcome 
measures. We hypothesized that the internet-based self-management program was superior to 




 Individuals with SSc were recruited from the University of Michigan and the Medical 
University of South Carolina (identified by scleroderma clinics), and via websites and social 
media sources of the Scleroderma Foundation and Scleroderma Research Foundation (self-
identified SSc). Inclusion criteria were: residents of the United States, diagnosis of SSc, ≥18 
years of age, basic computer literacy, access to a computer with internet and email capabilities, 
communication skills in English, and a willingness to complete the study protocol. This study 
was conducted in accordance with the Helsinki Declaration and all participants provided 
informed consent. The study was approved by institutional review boards of the University of 
New Mexico, University of Michigan, the Medical University of South Carolina, and is registered 
with clinical trials.gov (#NCT02494401). 
 
Outcome Measures  
Demographics 
 Demographic information, including age, gender, type of scleroderma (diffuse, 
limited/sine, overlap disease) as reported by the participant, length of time since disease onset, 
self-rated health, education level, marital status, and ethnicity, was collected. 
 
Patient-Reported Measures 
 Self-efficacy is the belief that one can carry out a behavior necessary to reach a 
desired goal, even when a situation contains unpredictable and stressful elements(7). Self-
efficacy is a major determinant of behavior and behavioral change, and acts as a key mediator 















This article is protected by copyright. All rights reserved 
administered the PROMIS® Self-Efficacy for Managing Chronic Conditions measure, which is 
comprised of 5 domains: Managing symptoms, Daily activities, Medications and treatments, 
Emotions, and Social interactions. Each domain consists of 8 items scored from 1 (not at all 
confident) to 5 (very confident), with higher scores indicative of greater self-efficacy. The scales 
were standardized to the US population so that the mean was 50 and the SD was 10 units, and 
results were scored using http://www.healthmeasures.net/explore-measurement-
systems/promis. We used the domain for managing symptoms as the primary outcome 
measure. 
 The PROMIS-29 Profile v2.0® measure contains 29 items, one on pain intensity 
and 4 items in each of the following domains: physical function, anxiety, depression, 
fatigue, sleep disturbance, pain interference, and satisfaction with social roles(11). With 
the exception of physical function, which does not include a time frame, all item banks 
referenced the past 7 days. Items were scored from 1 (unable to do/never/not at all) to 
5 (without any difficulty/always/very much). All scales, except the pain intensity item, 
were standardized to the US population so that the mean was 50 and SD was 10 units, 
and they were scored using http://www.healthmeasures.net/explore-measurement-
systems/promis. 
 The Patient Health Questionnaire-8 (PHQ-8) is an 8-item questionnaire that is 
commonly used to measure depressive symptoms(12). A score of ≥10 is consistent with 
depressed mood.  
 The Patient Activation Measure (PAM) is a 13-item measure that assesses patient 
knowledge, skill, and confidence for self-management(13). Each item is scored from 1 (strongly 
disagree) to 4 (strongly agree). Scores are then summed, yielding a total that can range in value 
from 13.0 to 52.0. The summed score is finally transformed into a 0- to 100-point scale with 
higher scores indicating more confidence and knowledge in patients managing their condition. 
PAM scores were categorized into 4 levels—Level 1: Individual is disengaged and overwhelmed; 
Level 2: Individual is aware but struggling; Level 3: Individual is taking action; and Level 4: 
Individual is maintaining behavior (https://www.insigniahealth.com/products/pam-survey). The 
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 The European Quality of Life-5 Dimensions (EQ-5D) and Quality Adjusted Life 
Years (QALYs) provides a generic health-related quality of life assessment. The EQ-5D 
incorporates patient-reported outcomes along the domains of mobility, self-care, 
activity, pain, and anxiety. Using a conversion algorithm, patient responses are 
converted into a health utility measure, ranging from 0.0 (death) to 1.0 (full or optimal 
health).  
The Brief Satisfaction with Appearance Scale (SWAP) is a 6-item scale measuring body image 
concerns and social discomfort with body parts. It is scored from 0 to 36, with higher scores 
associated with greater dissatisfaction.  
 Participants in both groups completed questionnaires at baseline and post-intervention 
at 16 weeks. A program evaluation was performed by asking participants in the intervention 
group to complete a questionnaire to gauge the content and presentation of the modules and 
to provide other feedback to the investigators. 
 
Sample Size 
 Sample size calculation was based on an analysis of pre–post changes in the Chronic 
Disease Self-Efficacy Scale in our pilot internet study(5). Based on pilot data, we expected that 
the effect size (ES; mean pre–post change/SD at baseline) in the intervention group would be 
approximately 0.50 (medium effect size as suggested by Cohen(15), and we anticipated a 
negligible effect size in the control group (ES = 0.10). Using a significance level of .05, we 
estimated that recruiting 100 participants in each group would yield an 80% power for 
detecting this difference between the intervention and the control group. Assuming a 




 Participants who met the inclusion criteria were sent instructions to review an 
electronic consent form through a Qualtrics® platform. Once signed consents were obtained, 
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the consent were randomized to either an intervention or control group. Randomization was 
performed using a 1:1 ratio and via computer-generated block randomization, with 
stratification based on the PHQ-8 score (respectively, <10, ≥10) to ensure that subjects with 
depressive symptoms were equally distributed in the two groups. Stratification based on the 
PHQ-8 score was pursued because we hypothesized that participants who reported being 
depressed may have poor coping and self-management skills. Although the assignment to 
either group was random, to ensure that the proportion of patients with more or fewer 
depressive symptoms was approximately the same in both groups, after every 50 patients were 
recruited, the assignment of patients to each group up to that point was cross-tabulated with 
respect to PHQ-8 scores. In addition, block randomization of patients occurred in groups of 50. 
This allowed us to divide the intervention groups into 5 waves of 25 participants so that the 
Discussion board groups were small enough to encourage participation.  
 
Intervention 
 Patients randomized to the internet program received a link to the self-management 
website, as well as a password and user name. The site could only be accessed via a secured 
website. The 15 modules including: Basic Overview, Coping and Body Image, Exercise, Self-
Advocacy, Pain Management, Activities of Daily Living, Fatigue and Energy Conservation, Tips 
for Families and Caregivers, Muscle and Lung Disease with a focus on African Americans, 
Gastrointestinal Tract, Raynaud’s Disease, Sexuality and Scleroderma, Mouth and Teeth Care, 
Clinical Trials, and Emergencies were presented with 1 module focus made available per week. 
Two investigators (JLP, SLN) posted weekly questions regarding the modules on the Discussion 
Board and moderated the online discussion as necessary (content is included as Appendix 1). 
Participants were asked to log on to the Discussion Board at least once weekly.  
 Those allocated to the control group received a copy of The Scleroderma Book: A Guide 
for Patients and Families, by Dr. Maureen Mayes. This book is the authoritative, educational 
book most requested and used by patients with a diagnosis of scleroderma. To date, it is the 
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coping with the disease, and resources for patients. Participants randomized to the control 
group were sent the textbook. The control group was given 16 weeks to read the book.  
A variety of strategies were used to maintain participant engagement in both groups during the 
intervention, including phone calls or email contact at 4-, 8-, and 12-weeks, and an incentive of 
$150 in the form of gift cards during the course of the study.  
 
Statistical analysis 
 Summary statistics of the baseline demographic variables were computed for all the 
patients enrolled in the study. For each of these variables, summary statistics were calculated 
for the group of patients as a whole, and stratified by treatment group (intervention vs. 
standard care). Group differences for these characteristics were tested using either t-tests, 
Wilcoxon tests, proportion test, or Chi-square tests, depending on the type of data (continuous 
vs. categorical, normally distributed vs. not). 
 To compare group differences between the intervention and control group post-
intervention, we considered only subjects with both baseline and follow-up data available. For 
those subjects, we computed the change in the scores from baseline to follow-up for 
continuous variables. For categorical variables, such as the PAM levels, we generated 
contingency tables presenting the joint distribution of the categorical classes at both baseline 
and follow-up (e.g. what percent of patients belonged to PAM level 1 at baseline and PAM level 
1 at follow-up, and so forth). For both continuous and categorical variables, we tested whether 
there was a significant difference between the two groups either in the change in the scores or 
in the joint distributions of the categorical variables. Specifically, for continuous variables, we 
assessed whether there was a significant difference in the change in the scores in the control 
and internet groups by performing either t-tests, if the change in score appeared to be 
continuous and normally distributed, or Wilcoxon tests if a normal distribution did not seem 
appropriate. For categorical variables, we assessed whether there was a significant difference in 
the joint distribution of the categorical variable at baseline and follow-up in the two groups 
using Fisher’s exact due to small counts in some of the contingency table cells. For each test, we 
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Results 
 A total of 267 subjects agreed to participate in the study and were randomized to either 
group. Of these 267 participants who completed baseline questionnaires and were randomized 
to the intervention (internet) or control (book) condition (Figure 1), 123 (93%) in the internet 
and 124 (94%) in the control completed the 16-week RCT. The two groups were similar at 
baseline with respect to the demographic variables (Table 1). Overall, the mean (SD) age was 
53.7 (11.7) years, 91% were female, 82.8% were White, and 79.4% had some college or higher 
degree. The mean (SD) disease duration after diagnosis of SSc was 8.97 (8.50) years with 44.9% 
in the internet group and 43.1% in the control group, classifying themselves as limited/sine and 
diffuse SSc, respectively.  
 Regardless of group, participants had similar mean scores on PROs except for the EQ-5D 
VAS which showed statistically higher scores in the internet group (Table 2). For the PROMIS 
self-efficacy and PROMIS-29 measures, the scores ranged from being similar between groups 
(PROMIS Self Efficacy Managing Medications and Treatment) to being 1.00 SD below the mean 
US population (PROMIS-29 Physical function scale). The mean (SD) PHQ-8 score was 8.67 (5.18), 
and 43.1 % had depressed mood. Regarding the PAM scores, 18.7% and 59.6% were in PAM 
Level 3 and PAM Level 4, respectively.  
 Table 2 shows the mean change scores for the two groups between baseline and post 
intervention at 16 weeks for all variables. There were no statistical differences between the 2 
groups for the primary outcome measure (PROMIS Self Efficacy Managing Symptoms: mean 
change of 0.35 in the internet group vs. 0.94 in control group, p=0.47) and other PROs, except 
for a significant difference between the internet and control groups for changes in the way the 
EQ-5D index changes from baseline to follow-up.  
 As we recruited a group of participants who had a high level of patient activation 
(approximately 60% had PAM Level 4), and long disease duration, we assessed the participants 
with early disease (<2 years and <5 years), PHQ< 10, PHQ≥10, and PAM Level 1 and 2 (Table 3). 
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Managing Symptoms favoring the control group in early disease duration (p=0.03) (Table 4), 
and EQ-5D Self Care favoring the control group for those with PHQ≥10 (p=0.02). 
 
Discussion Board Evaluation 
 Of the 134 participants randomized to the internet group, 81 (61.4%) visited the 
discussion board, with 79 (59.8%) posting at least one comment over the 16-week RCT. An 
average of 8 comments were posted per user, with an average of 58.21 minutes reviewing each 
module. At the end of the 16-week RCT, 100 (74.6%) participants completed a course 
evaluation, in which they were asked to rate each module as helpful, slightly helpful, not helpful 
at all, or did not review this module (Appendix Figure 1). An average of 75.4% rated the 
modules as being helpful. Key modules, with over 60 hours of time spent on each module, 
included Scleroderma: A Basic Overview, Coping and Body Image/Appearance, Exercise, Self-
Advocacy, and Dysphagia and the Digestive Tract. The course evaluation showed that 67.9% of 
participants agreed the Discussion Board addressed important issues about scleroderma, with 
44.5% agreeing the Discussion Board increased their understanding of scleroderma, and 63.0% 
agreeing the Discussion Board was a good way to learn from people with scleroderma. When 
asked about their impression of the self-management course, an overwhelming 93.0% agreed 
that the modules were of importance to them; 94.0% agreed that the information was 
presented clearly with the website being easy to use, and at an appropriate reading level 
(Figure 2). We also provided access to the internet site for the participants who were 
randomized to the control group. 49 participants responded to the survey and 91.84 % agreed 
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 Using input from US Scleroderma Foundations and patient partners, we refined a 
previously developed internet program and tested it in the current RCT. Although we could 
not show any difference in the primary and secondary outcome measures, participants from 
the intervention showed overwhelming support and enthusiasm for the content and 
presentation on the website (Appendix Figure 1).  
 Based on input from the patient and stakeholder partners, we stratified the 
randomization with respect to PHQ-8 being below 10 vs. at least 10, as we hypothesized that 
participants who have depressed mood may exhibit poor coping skills. Although participants 
with PHQ-8 scores of ≥ 10 had lower scores on self-efficacy and PROMIS-29 scores (data not 
shown), there was no benefit in the internet group compared to control group. Our baseline 
data suggests that we recruited a group of highly motivated (approximately 60% had PAM Level 
4), highly educated participants (80% had attended at least some college), who have been 
dealing with their disease for a long time (the mean time since diagnosis was 9 years). When we 
focused only on participants with early disease (<2 years and< 5 years), PHQ≥10, and PAM Level 
1 and 2, we found no difference between internet group vs. control group, although the sample 
sizes in these subgroups were very small and may be related to Type 2 error.  
 
 Patients with chronic diseases such as SSc make daily decisions or self-manage their 
illnesses. A central concept in self-management education is self-efficacy(16), which is a major 
determinant of behavior and behavioral change, and acts as a key mediator of the attainment 
of self-management skills in chronic diseases(8, 9). Published work suggests that self-
management skills are associated with improved clinical outcomes, and reduce costs for 
arthritis(16).  
Because SSc is a rare disease (designated as an orphan disease by the Food and Drug 
Administration), Scleroderma Foundation Chapters and/or support groups do not exist 
throughout every state in the United States. Many people with SSc have not met anyone with 
the disease(17, 18). Patients living outside major metropolitan areas may not have access to 
health care providers with a specialized knowledge of SSc. Thus, SSc patients feel isolated from 
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on scleroderma are offered via written materials, webinars and annual conferences through the 
Scleroderma Foundation, and state and/or local chapters of the Scleroderma Foundation and 
the Scleroderma Research Foundation. These offerings are credible sources of information, but 
patients may need to search through a website or wait for the next conference, meeting, or 
webinar. Having an internet program that contains all the information and resources on self-
management in one site and one format that can be quickly updated may be very useful to 
meet the needs of patients with scleroderma and their families and/or caregivers. Creators of 
the Arthritis Self-Management Program and Chronic Disease Self-Management Program 
developed internet versions of their successful programs, with outcomes similar to those 
achieved with the group format(19, 20). The advantages of internet programs are that they are 
easily accessible; can be shared with family members, caregivers, and/or health professionals; 
and can be viewed as many times as needed for reinforcement or as symptoms change with 
disease progression. However, the existing self-management programs for arthritis and chronic 
illness do not address the specific needs of scleroderma patients related to body image 
changes, skin and wound management, gastrointestinal involvement, lung involvement, 
Raynaud’s phenomenon and ulcerations, and disability. This was exemplified by a recent study 
showing that information available on the internet is not meeting the health care needs of 
systemic scleroderma patients(21).  
 
Recommendations for future work 
 Our study also provides insight into the design of the next trial. First, it highlights that 
the majority of the participants with SSc using the internet materials were well-educated, 
classified themselves as white, and were well-versed in management of their disease 
(approximately 80% had attended college or higher education, 83% were white, and 60% were 
in PAM Level 4). Future studies should focus on recruiting participants with lower PAM levels 
(likely to be non-white and less educated participants) who have lower self-efficacy scores(10), 
and who would likely benefit from self-management courses. Second, participants with earlier 
disease may benefit, as published data suggests that patients’ adjustment to a chronic disease 
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 Our RCT has many strengths. We recruited and retained over 90% of participants over a 
period of 16 weeks. In addition, we collaborated with patient partners and stakeholders and 
recruited participants from both academic and non-academic settings, providing 
generalizability for our results. Lastly, this is one of the largest studies evaluating a self-
management or behavioral intervention in people with SSc. 
 In conclusion, our RCT showed that the internet-based self-management website was 
not superior to the patient-focused textbook in improving self-efficacy and other measures. 
High patient activation scores and near normal self-efficacy scores may have contributed to this 
result. However, participants were overwhelmingly enthusiastic, indicating a need for an 
internet program that is credible and easily accessible.  
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Table 1 Baseline characteristics of participants in the randomized clinical trial 









Age Mean± SD (yrs)  53.7 (11.7) 54.3 (10.1) 52.9 (13.1) 0.33 
Female Sex, no.(%) (n ) 91 (243) 91.8 (123) 90.2 ( 120) 0.82 
Race, no.% (n )         
White   82.8 (221) 83.6 (112) 82.0 (109) 0.85 
African American 7.5(20) 5.2 (7) 9.8 (13) 0.24 
Asian/Asian American 1.5 (4) 0.7 (1) 2.3 (3) 0.61 
Native Hawaiian or Other Pacific Islander 0.7 (2) 1.5 (2) 0 0.48 
Other 1.5 (4) 0.7 (1) 2.25 (3) 1 
Multiracial 6(16) 8.2 (11) 3.8 (5) 0.2 
Ethnicity % (n )         
Hispanic  4.1 (11) 5.2 (7) 3.0 (4) 0.55 
Non-Hispanic 77.5 (207) 78.4 (105) 76.7 (102) 0.86 
Other 15 (40) 14.9 (20) 15.0 (20) 1 
Unknown 3.4(9) 1.5 (2) 5.3 (7) 0.17 
Education % (n )         
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College/University ( 13-16)  48.3 (129) 49.3 (66) 47.4 (63) 0.85 
Graduate School (17-22)  27 (72) 26.9 (36) 27.1 (36) 1 
Post Graduate School ( 23+)  4.1 (11) 3.7 (5) 4.5 (6) 0.99 
Marital Status % (n)         
Single, never married 11.6 (31) 7.5 (10) 15.8 (21) 0.05 
Married 63.7 (170) 70.9 (95) 56.4 (75) 0.02 
Widowed 3.4 (9) 1.5 (2) 5.3 (7) 0.17 
Divorced/Separated 21.3 (57) 20.1 (27) 22.6 (30) 0.74 
Employment status % (n)         
   Working full time (20 hours or more per 
wk.) 35.6 (95) 35.8 (48) 35.3 (47) 1 
   Working part time (less than 20 hours per 
wk.) 6.7 (18) 7.5 (10) 6.0 (8) 0.82 
On disability or sick leave 26.2 (70) 23.9 (32) 28.6 (38) 0.46 
Retired 22.1 (59) 23.9 (32) 20.3 (27) 0.58 
Not working but looking for work 2.3 (6) 1.5 (2) 3.0 (4) 0.67 
Other  7.1(19) 7.5 (10) 6.8 (9) 1 
Self-defined scleroderma sub type % (n )         
Limited/Sine % 44.9(120) 42.5 (57) 47.4 (63) 0.5 
Diffuse % 43.1 (115) 42.5 (57) 43.6 (58) 0.96 
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Unknown 0.4 (1) 0.7 (1) 0 1 
Patient-Reported Disease duration, Mean± 
SD (yrs)          
After First Diagnosis from Doctor 8.97 (8.50) 8.72 (7.81) 9.23 (9.17) 0.63 
After First Scleroderma Symptoms 11.91 (10.10) 12.20 (9.33) 11.62 (10.84) 0.64 
Overall health % (n)         
Excellent 1.1 (3) 0.7 (1) 1.5 (2) 1 
Very Good 12.4 (33) 12.7 (17) 12.0 (16) 1 
Good 42.7 (114) 44.8 (60) 40.6 (54) 0.57 
Fair 37.4 (100) 34.3 (46) 40.6 (54) 0.35 
Poor 6.4 (17) 7.5 (10) 5.3 (7) 0.63 
U.S. geographical region % (n)         
Midwest 50.2 (134) 54.5 (73) 45.9 (61) 0.2 
Northeast 8.6 (23) 5.2 (7) 12.0 (16) 0.08 
South 20.6 (55) 20.9 (28) 20.3 (27) 1 
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Table 2. Mean Patient-Reported Outcomes at Baseline, 16 weeks, and changes score over 16 weeks 
Mean Patient-Reported Outcomes Baseline compared to 16 weeks 
Scales 
BASELINE 16 WEEKS CHANGE 
Internet group Control Group p-value Internet group Control group p-value Internet group Control group p-value 
PROMIS Self-
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N=124 
PROMIS-29      
 
    
 
    
 
Physical Function Mean=40.63; 
Sd=6.95; N=134 
Mean=40.17; 










Social Role Mean=43.74; 
SD=8.63; N=134 
Mean=44.39; 
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PHQ-8  Mean=8.61; 
SD=5.39; N=134 
Mean=8.72; 










EQ-5D      
 
    
 




























Usual Activities Mean=1.78; 
SD=0.50; N=134 
Mean=1.79; 










Pain Discomfort Mean=1.93; 
SD=0.48; N=134 
Mean=2.02; 


























































EQ-5D Index Mean=0.71; 
SD=0.18; N=134 
Mean=0.69; 










SWAP  Mean=17.1; 
SD=9.53; N=134 
Mean=16.81; 














Measure (PAM)     
 
    
 
    
 PAM 
Level 1,  
N (%) 14 (10.45) 14 (10.53) 1 10 (8.13) 12 (9.68) 0.82 NA NA 
 PAM  





















Level 3,  
N (%) 23 (17.16) 27 (20.30) 0.53 26 (21.14) 22 (17.74) 0.52 NA NA 
 PAM  
Level 4,  
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Table 3 Mean Patient-Reported Outcomes Disease Duration, PHQ-8, and PAM Levels at Baseline 
Scales Disease   
< 2 yrs Trt 
group 
(Baseline) 
Disease   






Disease     
< 5 yrs Trt 
group 
(Baseline) 
Disease     




























PAM     
level 1-2  
Trt group 
(Baseline) 
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(8.86%) 0.33 10 (18.18) 7 (14.0) 0.61 12 (46.15) 14 (50.0) 0.79 
PAM Level 




(7.59%) 0.58 6 (10.91) 8 (16.0) 0.57 14 (53.85) 14 (50.0) 0.79 
PAM Level 




(22.78%) 0.30 10 (18.18) 8 (16.0) 0.8 0 0 1.0 
PAM Level 
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Table 4 Mean Patient-Reported Outcomes Disease Duration, PHQ-8, and PAM Levels at 16-week follow-up 
 
Scales Disease   
< 2 yrs Trt 
group 
(Change) 
Disease   





Disease     
< 5 yrs Trt 
group 
(Change) 
Disease     

























PAM     
level 1-2  
Trt group 
(Change) 
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Figure 1. CONSORT flow diagram for participants in the trial. 
 
Assessed for eligibility, invited 
to participate by email or in 
person (n=544) 
Excluded / Ineligible (n=  277) 
♦  Did not complete baseline (n= 64) 
♦  Did not open email invitation (n= 82 ) 
♦  Did not respond to email invitation 
(n=131) 
Allocated to control (book) (n=133) 
♦ Allocated with a PHQ ≥ 10 (n= 78) 
♦ Allocated with a PHQ<10 (n= 55) 
Allocated to intervention (internet) (n=134) 
♦ Allocated with a PHQ≥ 10 (n= 74) 
♦ Allocated with a PHQ <10 (n= 60) 
 
 
Analysed (n= 123) 
 ♦ Excluded from analysis due to 
discontinuation of intervention or control 
and lost to follow up (n=11) 
 
 
Analysed (n= 124) 
♦ Excluded from analysis due to 
discontinuation of intervention or control 
and lost to follow up (n=9 ) 
Analysis 
Lost to follow-up (n= 9) 
♦ Unreachable (n=9) 
 
Discontinued intervention (n=2) 
♦ Time commitment (n= 2) 
 
Lost to follow-up (n=6) 
♦ Unreachable (n=6) 
Discontinued Control (n=3) 
♦ Refused control (book)= 2 




Randomized (n= 267) 
Allocation 


















Figure 2. Discussion Board Evaluation. This figure provides an illustration of the responses received by internet participants after completion 
of the 16-week RCT 
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